Scynexis says GSK on hook for $10M payment after phase 3 Brexafemme trial starts back up
A month after the FDA lifted its clinical hold on GSK’s vaginal yeast infection drug Brexafemme, the developer of the treatment, Scynexis, has resumed a phase 3 study, dosing its first new patient. The trial resumption triggers a $10 million milestone payment from GSK and another $20 million due in six months, Scynexis says, with the British pharma giant disputing the charges.
A month after the FDA lifted its clinical hold on GSK’s vaginal yeast infection drug Brexafemme, the developer of the treatment, Scynexis, has resumed a phase 3 study, dosing its first new patient. The trial resumption triggers a $10 million milestone payment from GSK and another $20 million due in six months, Scynexis says, with the British pharma giant disputing the charges.
